Lymphoid development is regulated by an array of cellular processes that include proliferation, differentiation, and cell death. Cell death is accomplished by apoptosis, a morphologically defined process that is widespread during embryogenesis and postnatal development (1) . Apoptosis serves to ensure the selection ofappropriate lymphoid populations during thymic development and to dampen the immune response in peripheral tissues (2, 3) . It is estimated that as many as 97% ofthe T cell precursors die during thymic development through apoptosis (4) . The assembly of TCR genes is largely a random process resulting in a large fraction of developing T cells that fail to assemble functional TCRs and are thought to be eliminated by apoptosis (4) . Developing CD4 +CD8 + thymocytes that express functional TCRs are further selected by positive and negative events involving the interaction of TCRs with peptides complexed with MHC molecules (5, 6) . Negative selection is a major mechanism to establish self-tolerance . Specifically, CD4+CD8+ thymocytes that bear TCRs with high affinity for self-peptide-MHC complexes are eliminated by apoptosis (2, 3, 6) . Developing T cells that successfully complete intrathymic selection processes are exported to the periphery as mature CD4+ or CD8 + T lymphocytes .
The recognition of antigenic peptides by TCRs in the context of MHC molecules is the fundamental event shaping the fate of developing T cells . A variety of stimuli and cellular interactions can trigger the death of T cells by activating the apoptotic process. These include deprivation of essential growth factors, signaling through cell surface receptors other than TCRs, and exposure to agents such as glucocorticoids, calcium ionophore, or genotoxic drugs (1) . The mechanisms that mediate and regulate apoptosis are still poorly understood, but it is thought that cell death is controlled by a genetic program that is induced within the dying cell (1, 7) . There is increasing evidence that a major function of the death program is to activate proteins that act as effectors of the apoptotic mechanism (8, 9) . However, apoptosis is further regulated by a set of genes that function as repressors of cell death (8) .
The bcl-2 protooncogene was the first member of an expanding family of genes that suppress the apoptotic mechanism (10) . Constitutive expression of bd-2 in lymphoid cells prevents or delays apoptosis induced by multiple stimuli (11) (12) (13) (14) . A role for Bcl-2 in the selection of T lymphocytes was suggested by its highly restricted cellular distribution within the thymus (15) (16) (17) (18) . Recent evidence suggest that Bcl-2 plays a role in positive selection in the thymus (19) (20) (21) (22) . The ability of Bcl-2 to influence negative selection in the thymus is controversial . Some investigators have found that enforced expression of bd-2 was inefficient in protecting self-reactive thymocytes from clonal deletion (13) , but others have reported partial abrogation of clonal deletion but not self-tolerance by bcl-2 overexpression (14, 19, 23) .
Mice deficient in Bcl-2 exhibit normal maturation of both B and T cell lineages, indicating that Bcl-2 is not essential for lymphoid development (24, 25) . A plausible explanation is that proteins other than Bcl-2 can function as survival signals during the selection and maintenance of T lymphocytes. A candidate is BC' -XL, a product of bcl-x, another gene of the bcl-2 family (26, 27) . Like Bcl-2, Bcl-xL localizes to mitochondrial membranes and perinuclear envelope (26) and inhibits the apoptotic death of hematopoietic cell lines after growth factor withdrawal (27) . In mice, bcl -xL is the dominant bcl-x mRNA expressed in embryonic and postnatal tissues, including the thymus (26, 28) . Recent analyses of chimeric mice with a disrupted mutation of bcl-x demonstrate a major role for bcl-x during lymphoid development (29) . However, the biological basis for the altered phenotype observed during T cell maturation in Bcl-xdeficient chimeric mice remains undetermined .
In these studies, we determined the distribution of the endogenous Bc1 -xL in thymocytes and T cells and examined the effect of constitutive expression of bcl -x, in the T cell lineage. We showed that thymocytes and peripheral T cells from transgenec ENt,-bcl-x L mice accumulated in the animal and exhibited prolonged survival in vitro. Furthermore, thymocytes overexpressing bd -xL exhibited increased survival after exposure to a diverse array of death-promoting stimuli that include glucorticoid hormones, ionizing radiation, calcium ionophore, and activation through CD3 molecules. In addition, we demonstrated that tolerance was maintained despite constitutive bd -xL expression since deletion ofself-reactive lymphocytes was unaffected in the thymus and peripheral lymphoid organs . Finally, we showed that Bcl-2 and Bcl -x, proteins exhibited discordant cellular distribution in the thymus and peripheral T cells. The implications of these findings for physiological pathways of T cell selection and survival are discussed.
Materials and Methods
Mice and Injections . C57BL/6, BALE/c, CBA/Ca and CBA/J mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Animals used for these studies were between 8 and 12 wk of age (unless otherwise indicated) . C57BL/6 mice expressing the ot and [3 transgenes for the H-Y TCR were a gift of Dr. Harald von Boehmer (Basel Institute for Immunology, Basel, Switzerland) (30) . They were bred and maintained in a pathogen-free environment at the University of Michigan . Glucocorticoids were administered by injection of 2 mg i.p . of dexamethasone (American Regent Laboratories, Inc., Shirley, NY). Hamster anti-mouse CD3 (clone 145-2C11 ; 100 1Lg) or anti-DNP (clone UC8-1139 ; 100 Rg), provided by Dr. R. Miller (University of Michigan), were injected intraperitoneally .
Construction of the SV40-Eht,-bcl-x L Transgene and Generation of Transgenic Mice . To target bcl-x, to the lymphoid compartment, the human bd -xL cDNA was cloned under the regulatory control of the SV40 promoter and immunoglobulin heavy chain enhancer using a SV40-EH cassette (31) . The 2.4-kb fragment containing the SV40-EH-bcl-x L insert was microinjected into F2 1974 hybrid zygotes from (C57BL/6 X SJL/J)Fl parents at a concentration of 2-3 ng/lt.l . After overnight incubation, the eggs that survived to a two-cell stage were transferred to day 0.5 postcoitum pseudopregnant CS-1 females. 3 wk after birth, genomic DNA was prepared from tail tissue, and the incorporation of the human bcl-x, transgene was assessed by dot blot analysis or PCR as previously described (27) .
Cell Preparations . Murine lymphoid organs were placed in sterile PBS, and the tissue was disrupted with the tip of the plunger of a sterile 1-ml syringe. Cells were washed in cold PBS and centrifuged three times at 400 g for 5 min to remove cellular aggregates . Single-cell preparations were counted and assessed for viability by trypan blue exclusion. The cells were cultured at 37°C in RPMI supplemented with 2 MM L-glutamine, 10 -5 M 2-ME, and 10% heat-inactivated FCS (Hyclone Laboratories Inc., Logan, UT) . In some experiments, cells were incubated with dexamethasone (American Regent Laboratories, Inc.) or ionomycine (Sigma Chemical Co ., St. Louis, MO) or irradiated before culture by exposure to a Co source at 250 rad. Cell proliferation in triplicate cultures was determined by adding Con A (10 p,g/ ml) to 4 X 10 5 lymphocytes in 96-well microplates (Falcon Plastics, Cockeysville, MD). Flow Cytometric Analysis . 10 6 cells were incubated with the indicated antibodies in 100 ILI of PBS with 1% BSA for 30 min on ice and washed twice with PBS/1% BSA. When indicated, 25 LLI of streptavidin RED670 was used for three-color analysis . Cells were analyzed with a FACScane flow cytometer and a minimum of 3 X 10" events per sample were counted using Lysys II software (Becton Dickinson & Co ., Mountain View, CA). Analysis of Bcl-x expression by flow cytometry was performed as previously described for Bcl-2 (32), using a mouse IgG2b anti-Bcl-x mAb (Transduction Lab., Lexington, KY), followed by a biotinylated goat anti-mouse IgG2b (CALTAG Laboratories, South San Francisco, CA) . Apoptosis levels in thymocytes were assessed by propidium iodide (PI)' staining as previously described (33) . Briefly, a pellet of 5 X 105 cells was resuspended in 600 N.l of HZO containing 50 lLg/ml of PI, 0.1% Triton X-100 (Sigma Chemical Co .), and 0.1% sodium citrate and then incubated at 4°C overnight in the dark . Cells were analyzed by flow cytometry.
Western Blotting Analysis . Bcl -xL protein expression was determined by Western blotting as previously described (32) . Briefly, proteins were transferred to nitrocellulose membranes by electrophoresis and then incubated at 4°C overnight with a rabbit anti-'Abbreviations used in this paper: HRP, horseradish peroxidase ; PI, propidium iodide ; TBS, Tris-buffered saline .
bd-xL Expression Is Regulated in the Thymus and Blocks Apoptosis Bcl-x polyclonal serum (provided by Dr . Craig Thompson, University of Chicago, Chicago, IL) diluted 1 :500 in 1 .5% milk Trisbuffered saline (TBS) with 30 pd of normal goat serum (Sigma Chemical Co .) or with a mouse anti-R-tubulin antibody (Sigma Chemical Co .) at 1 Rg/ml diluted in 1 .5% milk-TBS . After five washes in TBS with 0 .05% Tween 20, the membrane was incubated for 1 h at room temperature with goat anti-rabbit antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch Laboratories, Inc ., West Grove, PA) diluted 1 :50,000 in 1 .5%1 milk-TBS or with goat anti-mouse antibody conjugated to HRP (Jackson ImmunoResearch Laboratories) diluted 1 :25,000 in 1 .5% milk-TBS . Bound antibody was detected by chemiluminescence using the ECL Western Blot kit (Amersham Corp .) .
Results
Discordant Regulation ofBcl-x and Bcl-2 during T Cell Development. In thymic tissue of normal mice, Bcl -xL is the only Bcl-x protein detected by Western blot analysis using polyclonal antisera (34) . To examine the expression of the endogenous Bcl-xL protein in subsets of thymocytes, cells were labeled with anti-Bcl-x mAb, anti-CD4, and anti-CD8 antibodies . The expression of Bcl-xL was low in CD4 -CD8 -cells, increased in CD4 + CD8 + immature thymocytes, and downregulated in more mature CD4+CD8 -or CD8 + CD4 -thymocytes ( Fig . 1) . Furthermore, the BC' -xL protein was not detected in unstimulated peripheral CD4 + or CD8 + T cells ( was not detected in the spleen and lymph nodes of normal mice but was expressed in bcl-x-transgenic animals ( Fig. 2 B) . Lastly, the bd-xL transgene was not found in purified populations of splenic B cells and in several nonlymphoid organs, including brain, liver, kidney, and lung, as determined by comparison to endogenous levels of Bcl -xL observed in control mice (data not shown) .
Constitutive Expression of Bcl -xL Leads to Accumulation of Thymocytes and Peripheral T Cells . The expression of the bd-xL transgene in the thymus increased the number of total thymocytes . Table 1 shows the results obtained for transgenic mice compared with control littermates . In bcl-x-169, the total number of thymocytes increased by 46% (41 .2 X 10 6 vs . 60 X 10 6 in transgenic mice), and the three major subsets of thymocytes (CD4+CD8+, CD4+CD8 -, and CD4 -CD8 + ) were augmented over control littermates . In bcl-x-86 mice whose thymocytes expressed less Bcl -xL protein than bcl-x-169 (Fig . 2 B) , the total number of thymocytes at 6 wk was similar to nontransgenic littermates (data not shown) . However, by 10 wk of age, the total number of thymocytes increased by 58% (from 43 X 10 6 in control to 68 X 10 6 in transgenic mice) and displayed a slight increase in all thymocyte subsets when compared with the effects observed in bcl-x-169 . Thus, constitutive (14) . EN, is the immunoglobulin heavy enhancer and SV40 the early SV40 promoter . (B) Expression of Bcl -xL was assessed by Western blot analysis with a polyclonal anti-Bcl-x antibody followed by goat antirabbit serum conjugated to HRP. Lysates from 10 6 cells were loaded in each lane . In the left lane, lysate from FL-5 .12 cells transfected with the murine bcl-xL cDNA (26) is shown as a positive control indicated as Bcl-XL. As a control, expression of (3-tubulin was also assessed with a mouse anti-l3-tubulin antibody followed by goat anti-mouse serum conjugated to HRP.
Bcl-xL expression during T cell development resulted in uniform accumulation of thymocytes, and its effect on thymocytes correlated with the amount of Bcl -xL expressed in the thymus. The size of the peripheral T cell pool was increased by deregulated bcl-x,. The total number of lymphocytes in bcl-x-169 mice increased in lymph nodes (from 10 X 106 in control littermates to 29 X 106 ) and spleen (from 61 X 10 6 to 85 X 10 6) ( Table 2 ) . The increase in lymphoid cells reflected an accumulation of both CD4 and CD8 mature T cells. The increase in T cells was more pronounced in lymph nodes (5 .5-fold) than in spleen (2-fold) . Similar effects on peripheral T cells were observed in bcl-x-86 mice . However, the accumulation of mature T cell subpopulations was less pronounced in bcl-x-86 than in bcl-x-169 mice . Whereas the percentage of B cells in peripheral lymphoid organs fell drastically, the absolute number of B cells did not differ significantly between transgenic and control mice . Furthermore, different subsets of developing and mature B cells were unaltered in transgenic mice, indicating that the phenotypic changes mirrored the pattern of transgene expression (data not shown) . Thus, in contrast to Bcl-2 (13, 14) , constitutive Bcl -xL expression in the T cell lineage increases the number of thymocytes and mature CD4 and CD8 T cells in peripheral organs .
Bcl -xL Increases the Survival of Thymocytes and Peripheral T Cells In Vitro. To assess the effect of bd -xL on their survival, thymocytes from bcl-x,:transgenic and control littermates were cultured in RPMl medium supplemented with 10% FCS, and their viability was assessed by trypan blue exclusion. There was an improved survival of transgenic thymocytes compared with control thymocytes . By day 6 of culture, 50% of thymocytes from bcl-x-169 and 36% from bcl-x-86 mice were still viable, whereas <5% of the control thymocytes survived (Fig . 3) . Similarly, splenic T cells from bcl-x-transgenic mice exhibited increased survival combd -xL Expression Is Regulated in the Thymus and Blocks Apoptosis *Results were obtained by two-color flow cytometric analysis of thymocytes simultaneously labeled with FITC-conjugated anti-CD4 and PE-conjugated anti-CD8 antibodies . Values shown represent the mean ± SD for 10 animals. *Differences between transgenic and control littermates were statistically significant (p <0 .01) as assessed by Student's t test . bcl-x-169-transgenic and control littermates were 6 wk old. bd-x-86-transgenic and control littermates were 10 wk old. Grillot et al.
pared with T cells from control littermates (data not shown) . However, the capacity ofboth transgenic and control splenic T cells to proliferate in response to Con A in culture was virtually identical (data not shown) .
Bd -xL Protects Thymocytes against Dexamethasone, y Irradiation, and Calcium Ionophore-induced Cell Death In Vitro. Glucocorticoid hormones are known to cause a rapid depletion of thymocytes by apoptosis (37) . To evaluate whether bclxL inhibits DNA fragmentation associated with glucorti- coid-induced apoptosis, thymocytes were treated with 0.1 p,M of dexamethasone in culture for up to 18 h . Flow cytometric analysis revealed that dexamethasone-treated thymocytes displayed a sub-Go DNA peak, which is known to correspond to fragmented DNA in thymocytes (38) . At 6 h, only 10% ofthymocytes from bcl-x-169 mice were apoptotic in the presence of dexamethasone compared with 75% of control thymocytes. At 18 h, 40% of the dexamethasonetreated thymocytes from bcl-x-169 mice contained fragmented DNA as assessed by staining of nuclei with PI versus 95% of dexamethasone-nontransgenic thymocytes (Fig.  4 A) . A lesser level of protection against dexamethasoneinduced DNA fragmentation was observed for thymocytes from bcl-x-86 at 6 and 18 h of culture (Fig. 4 A) . Because glucocorticoids and irradiation appear to induce thymocyte apoptosis in part by different pathways (9), the ability of bd -xL to protect against irradiation-induced cell death was evaluated in thymocyte cultures . At a dose of 250 rod, >35% and 80% of control thymocytes displayed fragmented DNA at 6 and 18 h, respectively, after irradiation (Fig. 4 B) . However, thymocytes from bcl-x-169 mice were remarkably resistant to irradiation (Fig. 4 B) . Thymocytes from bcl-x-86 mice were also more resistant to irradiation than cells from control littermates (Fig. 4 B) . In addition, thymocytes from bcl-x-transgenic mice were resistant to death induced by calcium ionophore . After 10 h of exposure to 2 Ntg/ml of ionomycin, 88 ± 5% of the control thymocytes were apoptotic versus 9 ± 2% of the thymocytes from bcl-x-169 mice. IgM tion, and thymocyte populations were examined 48 h later by flow cytometric analysis. Dexamethasone treatment eliminated 70 ± 10% of total thymocytes from control mice compared with PBS-treated animals (from 45 X 106 to 14 X 106). In contrast, transgenic thymocytes were markedly protected from dexamethasone, with a decrease of only 15 -,--3% (from 61 X 106 to 51 X 106) . Further analysis revealed that CD4 + CD8+ thymocytes from control mice were almost entirely eliminated by dexamethasone, whereas 72% of this population remained viable in bcl-x-transgenic animals (Fig. 5) . In paralleled experiments, treatment with dexamethasone deleted equally B22010"'IgM -B cells from transgenic and control animals, demonstrating that the protection conferred by bcl-xL was lineage specific and mirrored transgene expression (Fig. 5 ) .
Bcl -xL Protects against Anti-CD3-induced Apoptosis In Vivo .
Triggering of CD4 + CD8 + thymocytes with anti-CM induces apoptosis in vitro and in vivo (2, 39) . To assess Bclx L ability to block anti-CD3-induced apoptosis, transgenic mice and control littermates were injected with anti-CD3, and their thymuses were examined 48 h later . As shown in Table 3 , 73% of CD4+CD8+ thymocytes from bcl-x-169 mice were still present 48 h after anti-CD3 treatment, whereas only 2% of this population remained in nontransgenic animals. As has been shown by others (2, 39), double-negative and single-positive thymocyte populations were largely unaffected by anti-CD3 treatment (Table 3) . Hence, overexpression ofBcl-x, can block anti-CD3-induced apoptosis .
Bcl-xL Fails to Protect Thymocytes from Clonal Deletion Induced by Endogenous Superantigens . An important form of thymocyte apoptosis is the deletion of developing T cells that express high-affinity TCRs for self-antigens (2, 3) . Signaling through CD3 in CD4 + CD8 + is thought to transduce signals that mimic those of negative selection, and Bcl-x, is able to block anti-CD3-induced apoptosis. Therefore we determined the ability of the bcl -x, transgene to overcome the deletion of self-reactive T cells . We evaluated the deletion of T cells reactive with superantigen Mls-1 bcl-xL Expression Is Regulated in the Thymus and Blocks Apoptosis (30, 48) was assessed by mating C57BL/6 mice homozygous for a H-Y ct/P-TCR transgene (30) to heterozygous bcl-x-169-transgenic mice.
In the H-Y male offspring, CD4+CD8+ and CD4 -CD8+ thymocytes from both bcl-x, and non-bcl-xLtransgenic mice were markedly deleted, compared with those from non-H-Y C57BL/6 male mice ( Table 5 ) . The number of CD4 +-CD8-thymocytes from both types of H-Y TCRtransgenic mice was essentially identical to that of nontransgenic controls, since clonal deletion induced by H-Y antigen is restricted to MHC class I molecules (30, 48) . Thus, Bcl -xL fails to abrogate clonal deletion of T cells reactive to self-H-Y antigen .
Discussion
These studies demonstrated that bcl -x, can inhibit several forms of T cell death in thymocytes and/or peripheral T cells. These include the spontaneous apoptosis in the absence of growth factors in vitro and the apoptosis induced by glucocorticoids, y irradiation, calcium ionophore, and anti-CD3 antibody. All of these stimuli have been shown to induce apoptotic cell death in thymocytes (13, 14) . We also showed that endogenous Bcl -x, expression is regulated during T cell development in a pattern different from that ofBcl-2. A major role for bcl-x in thymocyte development has been demonstrated in chimeric mice that are deficient in Bcl-x (29) . In these studies, the absence ofBcl -x, preferentially affected immature populations of thymocytes and 1980 pre-13 cells (29) . Our results provide an explanation for the findings in the T cell lineage in that Bcl -x, was expressed predominately in CD4+ CD8 + thymocytes, the developmental stage particularly affected by the absence of Bcl-x (29). Deregulated Bcl -x, expression led to a perturbation of T cell homeostasis characterized by accumulation of thymocytes and mature CD4 + and CD8 + T cells in all lymphoid organs . Remarkably, despite this alteration, BC'-xL deregulation failed to inhibit clonal deletion ofself-reactive T cells against endogenous superantigens and H-Y antigen .
The basis for the failure or poor ability of Bcl -x, and Bcl-2 to block clonal deletion compared with T cell death induced by other stimuli, including anti-CD3, is unclear . During negative selection, thymocytes bearing TCRs with high affinity for a self-antigen are deleted (6) . Signaling through CD3 in CD4+CD8 + cells is thought to transduce signals that mimic those of negative selection . However, clonal deletion of thymocytes appears to involve CD4-CD8, CD28, and other cellular interactions in addition to the CD3-TCR complex (49, 50) . Thus, it is possible that self-peptide-MHC/TCR signaling during negative selection results in a powerful death signal that cannot be abrogated by the levels of Bcl-2 or Bcl -xL produced by the transgenes. It is also possible that certain signaling pathways such as those responsible for clonal deletion involve distinct death effector molecules that may not be inhibited by Bcl-2 or Bcl-X L . Experimental evidence for different intracellular mediators of T cell death has been recently provided for glucocorticoids, radiation, and TCR-CD3 engagement (9) . For example, thymocyte apoptosis triggered by exposure to y irradiation or certain DNA-damaging agents but not glucocorticoids requires the tumor suppressor protein p53 (51, 52) . Another example is the requirement of nur77 for TCR-mediated apoptosis, whereas it does not play a role in either glucocorticoid-or radiation-induced death (53, 54) .
Constitutive expression of bcl-2 and bcl -x, protected thymocytes from a number of apoptotic stimuli . However, in contrast to our results with bcl-x, mice, a ENt-bcl- quate expression of Bcl-2 in the thymus and peripheral lymphoid organs (14) . The reason for the altered T cell homeostasis in Eli-bd-xLtransgenic mice as opposed to the lack of effect observed in Ela,-bd-2 mice is unclear . However, mice that are transgenic for a construct containing bd-2 downstream of the proximal promoter of the lck tyrosine kinase gene (lckPr) showed an accumulation of T cells (mainly CD8 +) (13) , suggesting that both bcl-x and bcl-2 can affect T cell homeostasis . Nevertheless, given the different phenotype observed between EIA,-bcl-x and ElLbcl-2-transgenic mice, it can not be excluded that Bcl -x, is more effective than Bcl-2 in countering some forms of T cell death operating in vivo. For example, BCl_XL has been shown to be more efficient than Bcl-2 in protecting the immature B cell line WEHI 231 from apoptosis induced by certain chemotherapeutic agents (55) . Bcl-2 and Bcl-xL display a discordant expression pattern during T cell development . BCl_XL is primarily expressed in CD4+CD8+ thymocytes, downregulated in CD4+CD8 -and CD4 -CD8+ thymocytes, and undetectable in mature T cells. In contrast, Bcl-2 is expressed at high levels in early CD4 -CD8 -T cell precursors, medullary CD4 +CD8 -and CD4 -CD8+ thymocytes and peripheral T cells, but downregulated in cortical CD4 + CD8 + thymocytes (15) (16) (17) (18) . After the submission of this manuscript, another study was published (56) that showed that BCl_XL is primarily expressed by CD4 +CD8 + thymocytes and confirmed the essential role of bcl-x during thymic development (29) . BCI -xL can protect thymocytes from various apoptotic stimuli . Indeed, our results have shown that constitutive expression of Bcl -x, resulted in an accumulation of thymocytes belonging to all major subsets and mature T cells in the periphery . Thus, it is likely that its expression serves to maintain CD4 +CD8+ thymocytes before positive selection. Because Bcl -x, is downregulated in more mature single-positive thymocytes and mature T cells, we suggest that CD4 +CD8 + thymocytes that are not positively selected downregulate BCl_XL later in development and fail to upregulate Bcl-2 . In contrast, the subpopulation of CD4 +CD8 + thymocytes that undergo positive selection is known to upregulate Bcl-2, a survival signal associated with positive selection (19) (20) (21) (22) . Thus, these results suggest that Bcl-2 acts later in development than Bcl -xL and functions as a survival switch for CD4+-CD8 + thymocytes during positive selection .
Diminished BcI-2 expression in cortical CD4 +CD8 + thymocytes has been proposed to play a facilitating role in the death of thymocytes during clonal selection (16) (17) (18) 57) . Indeed, CD4 +CD8 + thymocytes are more sensitive to multiple forms of apoptosis, including those induced by glucocorticoids, y irradiation, and anti-CD3 signaling, than other thymocyte populations that express BcI-2 (18, 39, 58) . Given that overexpression of Bcl -x, can confer protection against multiple forms of apoptosis, it is intriguing that CD4 +CD8 + thymocytes are sensitive to apoptosis, despite expression of endogenous Bcl -xL protein . A possible explanation is that simultaneous expression of Bcl-2 and BCl_XL is more effective than Bcl-x, or Bcl-2 alone in protecting thymocytes from apoptosis . An alternative nonexclusive interpretation is that the ability of endogenous Bcl -xL to protect CD4+CD8 + thymocytes from death signals is countered by intracellular inhibitory proteins. There is accumulating evidence that the function of Bcl-2 and BCl_XL is modulated by several interacting proteins that include Bax (59), Bad (60) , and Bag-1 (61) . Interestingly, two proteins of the Bcl-2 family, Bad and Bax, are produced by thymocytes and can form heterodimers with Bcl-2 and BCI -xL (60, 62) . In tissue culture experiments, susceptibility of cells to death signals appears to be determined by competing dimerizations among the different proteins ofthe Bcl-2 family expressed by the cell (60) . Furthermore, Bad binds more strongly to BCl_XL than to Bcl-2, and its interaction with BCl_XL promotes cell death (60) . Although the precise regulation of Bad or Bax during thymocyte development is unknown, it is tempting to speculate that endogenous BCl_XL in CD4 +CD8 + is countered by interacting proteins, resulting in an increased susceptibility to cell death . Based on the present studies and those by others, we would propose a hypothetical model of T cell survival in which the threshold to apoptosis is controlled by a balance among survival proteins such as Bcl-2 or Bcl -x,, their inhibitory partners, and the "strength" of the death signal . In this model, endogenous levels ofBcl -x, in CD4 +CD8+ thymocytes maintain T cell survival but are not sufficient to protect cells from death signals . Our results suggest that overexpressed Bcl -xL can effectively compete for inhibitory proteins or compensate for Bcl-2 downregulation and promotes thymocyte survival.
